Acadia Healthcare Shares Surge After Einhorn's Endorsement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Source: seekingalpha
Acadia Healthcare (ACHC) shares surged approximately 12% on Wednesday after hedge fund manager David Einhorn endorsed the company, indicating growing market confidence in its future prospects.
The stock's rise follows a significant endorsement from David Einhorn, which has led to increased investor interest, as evidenced by nearly 6 million shares traded, far exceeding the 65-day average of 3.4 million shares. This surge also marks the second-largest intraday gain for 2026, reflecting a potential rebound in market expectations for Acadia.
This rally comes after a challenging year for Acadia, which saw a decline of over 64%. However, with new leadership under CEO Debra Osteen since January 2023, the company has gained approximately 9% year-to-date, suggesting a positive shift in its trajectory.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACHC
Wall Street analysts forecast ACHC stock price to fall
11 Analyst Rating
5 Buy
5 Hold
1 Sell
Moderate Buy
Current: 31.090
Low
13.00
Averages
18.10
High
25.00
Current: 31.090
Low
13.00
Averages
18.10
High
25.00
About ACHC
Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services. The Company owns and operates acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (CTCs), residential treatment centers and facilities providing outpatient behavioral healthcare services to serve the behavioral healthcare and recovery needs of communities throughout the United States and Puerto Rico. Its acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. Its CTCs specialize in providing medication-assisted treatment in an outpatient setting. Its specialty treatment facilities primarily consist of residential recovery facilities. It provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Its residential treatment centers treat patients with behavioral disorders in a non-hospital setting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acadia Healthcare Stock Surpasses Analyst Target Price
- Price Target Breach: Acadia Healthcare Company (ACHC) shares have reached $29.53, surpassing the average analyst 12-month target price of $28.73, indicating market optimism about the company's future performance, which may prompt analysts to reassess their target prices.
- Analyst Target Variability: Among the 15 analysts covered by Zacks, target prices range from $13.00 to $39.00, with a standard deviation of $5.404, reflecting differing market perspectives on the company's future, necessitating cautious evaluation by investors.
- Investor Signal: The stock's breach of the target price provides investors with a signal to reassess the company, prompting them to consider whether the current price is merely a stop on the way to a higher target or if it is time to think about taking profits.
- Analyst Rating Overview: Analysts' average rating for Acadia Healthcare ranges from 1 to 5, where 1 is Strong Buy and 5 is Strong Sell, indicating varied market opinions on the stock, and investors should pay attention to the latest research reports for more insights.
See More
Mid-Cap Healthcare Stocks Valuation Analysis
- Valuation Score Overview: According to Seeking Alpha's valuation grades, Acadia Healthcare Company (ACHC) and Waystar Holding (WAY) received an A rating, indicating their attractiveness relative to peers and suggesting potential investor interest for gains.
- Market Performance Highlights: Among mid-cap healthcare stocks with market capitalizations between $2B and $10B, BioCryst Pharmaceuticals (BCRX) stands out with a B+ valuation grade, reflecting its competitiveness and investment appeal in the biopharmaceutical sector.
- Valuation Metrics Analysis: The valuation scores are derived from a comprehensive analysis of multiple metrics, including P/E, PEG, EV/Sales, and EV/EBITDA, providing investors with a robust basis for informed investment decisions.
- Industry Trend Insights: As the healthcare sector continues to evolve, investor focus on mid-cap healthcare stocks is increasing, particularly those demonstrating strong valuation performance, which may attract greater investment inflows in the future.
See More
13D Management Fully Exits WEX Stake Worth $4.59 Million
- Share Sale Overview: On May 15, 2026, 13D Management disclosed the sale of 29,350 shares of WEX, valued at approximately $4.59 million, indicating a cautious outlook on WEX's future prospects.
- Market Performance Analysis: As of May 14, 2026, WEX shares were priced at $134.02, remaining flat over the past year and significantly underperforming the S&P 500, which rose 25% in the same period, reflecting market concerns about its growth potential.
- Financial Performance Highlights: Despite the poor stock performance, WEX reported a nearly 6% year-over-year revenue increase in Q1, reaching $673.8 million, while adjusted earnings per share rose 18% to $4.15, indicating robust fundamentals.
- Future Outlook and Market Reaction: WEX raised its full-year revenue guidance to up to $2.88 billion, yet the market reacted negatively to its earnings report with a 16% drop in stock price; however, if management can continue to enhance margins and cash flow, stock recovery may be on the horizon.
See More
13D Management Acquires Significant Stake in Acadia Healthcare
- New Investment Disclosure: On May 15, 2026, 13D Management disclosed a new position in Acadia Healthcare by acquiring 294,000 shares valued at approximately $5.32 million, indicating confidence in the company's future prospects.
- Holding Value Increase: As of the end of Q1 2026, the value of Acadia Healthcare's position reached $6.88 million, representing 10.7% of 13F reportable assets, highlighting its significance within the investment portfolio.
- Performance Improvement: Acadia Healthcare reported a 7.6% year-over-year revenue increase to $828.8 million in Q1, driven by higher patient volumes and improved pricing, prompting management to raise full-year adjusted EBITDA and earnings guidance.
- Expansion Capacity: The company added 82 newly licensed beds during the quarter, now operating approximately 275 facilities with around 12,400 beds; if management maintains this growth momentum, the recent stock underperformance could present a buying opportunity.
See More
David Einhorn Recommends Five Transitioning Companies
- Acadia's Recovery Potential: Einhorn highlighted Acadia Healthcare (ACHC), which has seen its stock plummet from nearly $90 to around $25, arguing that the market's reaction is excessive; if occupancy rates of new facilities rebound, EBITDA could increase by $200 million annually, potentially doubling the stock price.
- Centene's Profit Normalization: Einhorn believes Centene (CNC) will recover from rising healthcare costs and Medicaid pricing pressures, with margins expected to normalize in the coming years, projecting a stock price increase from $56 to between $85 and $102, indicating significant undervaluation.
- Fluor's Survival and Transformation: After nearly collapsing, Fluor (FLR) is positioned at the center of several infrastructure supercycles; Einhorn noted that the company has initiated a $1.4 billion buyback program, which could retire about 20% of outstanding shares, reflecting its recovery and future demand.
- Victoria's Secret Comeback: Einhorn discussed Victoria's Secret (VSCO), which is redefining its identity after cultural backlash, with new leadership aiming for a 10% operating margin, suggesting strong recovery potential as the brand stabilizes and grows under renewed management strategies.
See More
David Einhorn Bullish on Overlooked Companies
- Acadia Healthcare: Einhorn highlighted that Acadia's newer facilities are underutilized, needing occupancy rates raised to 70-80% and improved reimbursement negotiations, with a potential share price of $56, doubling the current value.
- Centene's AI Potential: He argued that Centene could significantly benefit from AI in automating claims processing, with a projected stock value between $85 and $102, indicating substantial upside from the current $56 if margins normalize.
- Fluor's Capital Spending Opportunities: Einhorn noted that Fluor is well-positioned to capitalize on a U.S. capital spending boom across various sectors, suggesting shares could reach $115 in a few years, as the market underestimates its exposure to potential super cycles.
- Versant Media's Cash Flow Advantage: He mentioned that Versant Media remains insulated from streaming competition due to its focus on news and live sports, estimating it could generate free cash flow exceeding 60% of its market cap over the next four years for share buybacks or acquisitions.
See More
Acadia Healthcare Stock Surpasses Analyst Target Price
- Price Target Breach: Acadia Healthcare Company (ACHC) shares have reached $29.53, surpassing the average analyst 12-month target price of $28.73, indicating market optimism about the company's future performance, which may prompt analysts to reassess their target prices.
- Analyst Target Variability: Among the 15 analysts covered by Zacks, target prices range from $13.00 to $39.00, with a standard deviation of $5.404, reflecting differing market perspectives on the company's future, necessitating cautious evaluation by investors.
- Investor Signal: The stock's breach of the target price provides investors with a signal to reassess the company, prompting them to consider whether the current price is merely a stop on the way to a higher target or if it is time to think about taking profits.
- Analyst Rating Overview: Analysts' average rating for Acadia Healthcare ranges from 1 to 5, where 1 is Strong Buy and 5 is Strong Sell, indicating varied market opinions on the stock, and investors should pay attention to the latest research reports for more insights.
See More
Mid-Cap Healthcare Stocks Valuation Analysis
- Valuation Score Overview: According to Seeking Alpha's valuation grades, Acadia Healthcare Company (ACHC) and Waystar Holding (WAY) received an A rating, indicating their attractiveness relative to peers and suggesting potential investor interest for gains.
- Market Performance Highlights: Among mid-cap healthcare stocks with market capitalizations between $2B and $10B, BioCryst Pharmaceuticals (BCRX) stands out with a B+ valuation grade, reflecting its competitiveness and investment appeal in the biopharmaceutical sector.
- Valuation Metrics Analysis: The valuation scores are derived from a comprehensive analysis of multiple metrics, including P/E, PEG, EV/Sales, and EV/EBITDA, providing investors with a robust basis for informed investment decisions.
- Industry Trend Insights: As the healthcare sector continues to evolve, investor focus on mid-cap healthcare stocks is increasing, particularly those demonstrating strong valuation performance, which may attract greater investment inflows in the future.
See More
13D Management Fully Exits WEX Stake Worth $4.59 Million
- Share Sale Overview: On May 15, 2026, 13D Management disclosed the sale of 29,350 shares of WEX, valued at approximately $4.59 million, indicating a cautious outlook on WEX's future prospects.
- Market Performance Analysis: As of May 14, 2026, WEX shares were priced at $134.02, remaining flat over the past year and significantly underperforming the S&P 500, which rose 25% in the same period, reflecting market concerns about its growth potential.
- Financial Performance Highlights: Despite the poor stock performance, WEX reported a nearly 6% year-over-year revenue increase in Q1, reaching $673.8 million, while adjusted earnings per share rose 18% to $4.15, indicating robust fundamentals.
- Future Outlook and Market Reaction: WEX raised its full-year revenue guidance to up to $2.88 billion, yet the market reacted negatively to its earnings report with a 16% drop in stock price; however, if management can continue to enhance margins and cash flow, stock recovery may be on the horizon.
See More
13D Management Acquires Significant Stake in Acadia Healthcare
- New Investment Disclosure: On May 15, 2026, 13D Management disclosed a new position in Acadia Healthcare by acquiring 294,000 shares valued at approximately $5.32 million, indicating confidence in the company's future prospects.
- Holding Value Increase: As of the end of Q1 2026, the value of Acadia Healthcare's position reached $6.88 million, representing 10.7% of 13F reportable assets, highlighting its significance within the investment portfolio.
- Performance Improvement: Acadia Healthcare reported a 7.6% year-over-year revenue increase to $828.8 million in Q1, driven by higher patient volumes and improved pricing, prompting management to raise full-year adjusted EBITDA and earnings guidance.
- Expansion Capacity: The company added 82 newly licensed beds during the quarter, now operating approximately 275 facilities with around 12,400 beds; if management maintains this growth momentum, the recent stock underperformance could present a buying opportunity.
See More
David Einhorn Recommends Five Transitioning Companies
- Acadia's Recovery Potential: Einhorn highlighted Acadia Healthcare (ACHC), which has seen its stock plummet from nearly $90 to around $25, arguing that the market's reaction is excessive; if occupancy rates of new facilities rebound, EBITDA could increase by $200 million annually, potentially doubling the stock price.
- Centene's Profit Normalization: Einhorn believes Centene (CNC) will recover from rising healthcare costs and Medicaid pricing pressures, with margins expected to normalize in the coming years, projecting a stock price increase from $56 to between $85 and $102, indicating significant undervaluation.
- Fluor's Survival and Transformation: After nearly collapsing, Fluor (FLR) is positioned at the center of several infrastructure supercycles; Einhorn noted that the company has initiated a $1.4 billion buyback program, which could retire about 20% of outstanding shares, reflecting its recovery and future demand.
- Victoria's Secret Comeback: Einhorn discussed Victoria's Secret (VSCO), which is redefining its identity after cultural backlash, with new leadership aiming for a 10% operating margin, suggesting strong recovery potential as the brand stabilizes and grows under renewed management strategies.
See More
David Einhorn Bullish on Overlooked Companies
- Acadia Healthcare: Einhorn highlighted that Acadia's newer facilities are underutilized, needing occupancy rates raised to 70-80% and improved reimbursement negotiations, with a potential share price of $56, doubling the current value.
- Centene's AI Potential: He argued that Centene could significantly benefit from AI in automating claims processing, with a projected stock value between $85 and $102, indicating substantial upside from the current $56 if margins normalize.
- Fluor's Capital Spending Opportunities: Einhorn noted that Fluor is well-positioned to capitalize on a U.S. capital spending boom across various sectors, suggesting shares could reach $115 in a few years, as the market underestimates its exposure to potential super cycles.
- Versant Media's Cash Flow Advantage: He mentioned that Versant Media remains insulated from streaming competition due to its focus on news and live sports, estimating it could generate free cash flow exceeding 60% of its market cap over the next four years for share buybacks or acquisitions.
See More
